42 results about "Increase dose" patented technology

A system and method of diagnostic imaging is provided that includes positioning a subject in an imaging device, performing at least one scout scan, and marking a user-defined region-of-interest. An attenuation characteristic of an attenuation filter is then automatically adjusted based on the user-defined region-of-interest. The present invention automatically selects a proper attenuation filter configuration, corrects patient centering, and corrects noise prediction errors, thereby increasing dose efficiency and tube output.

A system and method of diagnostic imaging is provided that includes positioning a subject in a scanning bay, comparing a center of mass of the subject to a reference point, and repositioning the subject in the scanning bay to reduce a difference in position between the center of mass of the subject and the reference point. The present invention automatically selects a proper attenuation filter configuration, corrects patient centering, and corrects noise prediction errors, thereby increasing dose efficiency and tube output.

A system and method of diagnostic imaging is provided that includes determining a position of a subject in a scanning bay and tailoring x-ray attenuation such that the specific position of the subject is taken into consideration. The present invention automatically selects a proper attenuation filter configuration, corrects patient centering, and corrects noise prediction errors, thereby increasing dose efficiency and tube output.

[Problem] As compared with the current oral sustained-release preparation containing tamsulosin hydrochloride which have been supplied to the medical setting at present, it is needed to provide a sustained-release pharmaceutical composition in which the efficacy is equivalent or even better, adverse events such as adverse reactions (e.g., postural hypotension) are reduced, dose can be increased and, if desired, ingestion of food is not limited in the dosage and it is also needed to provide a method for administration of tamsulosin hydrochloride in which the adverse reactions accompanied by therapy or prevention on the basis of an α1 receptor blocking action are reduced. [Means for Resolution] A sustained-release pharmaceutical composition, characterized in that, there are contained tamsulosin or a pharmaceutically acceptable salt thereof and a carrier for a sustained-release pharmaceutical composition and the ratio (Cmin / Cmax ratio) of the plasma tamsulosin concentration at 24 hours after the administration of the preparation per os (Cmin) to the maximum plasma tamsulosin concentration after the administration (Cmax) is about 0.4 or more.

A system and method of diagnostic imaging is provided that includes positioning a subject in an imaging device, performing at least one scout scan, and marking a user-defined region-of-interest. An attenuation characteristic of an attenuation filter is then automatically adjusted based on the user-defined region-of-interest. The present invention automatically selects a proper attenuation filter configuration, corrects patient centering, and corrects noise prediction errors, thereby increasing dose efficiency and tube output.

A system and method to manufacturing a device provide a substrate and perform at least one exposure step. Each exposure step projects a patterned beam of radiation, which was patterned using an individually controllable elements, onto a target portion of the substrate. The projected patterned beam includes a plurality of pixels. Each exposure step also: (a) ordinarily controls the elements, such that each pixel delivers a radiation dose no greater than a predetermined normal maximum dose to the target portion in the exposure step; and (b) exceptionally controls the elements, such that at least one selected pixel delivers an increased radiation dose, greater than the normal maximum dose. The increased dose may be delivered to compensate for the effect of a defective element at a known position in the array on a pixel adjacent a selected pixel. Alternatively, it may compensate for underexposure of the target portion at the location of a selected pixel resulting from exposure of that location to a pixel affected by a known defective element in another exposure step. The invention uses doses up to the predetermined normal maximum for normal printing, but reserves at least one increased dose for compensation purposes. Accordingly, even when a dead black pixel falls in the middle of a group of surrounding white pixels it can be compensated for by increasing the radiation dose delivered by one or more of those neighboring white pixels, above the normal fully white value.

This is a new technique in IMRT and 3D conformal gamma radiation dose delivery using a linear accelerator with no flattening filter. The technique improves patient radiation therapy by reducing radiation scattered to surrounding normal tissue and reducing electron contamination. It increases dose rate to shorten treatment time. Linear accelerators have for decades come with a photon flattening filter to make the photon profile of planar fluence to make the dose distribution more uniform. These filters, however, resulted in fluence attenuation and contamination of the beam. Now in the age of techniques such as intensity modulated radiation therapy (IMRT) the function of the flattening filter becomes redundant. The flattening filter now merely reduces the efficiency of the beam by reducing the fluence and increasing scattered radiation. Our technique involves removal of the flattening filter for complex treatments. It uses inverse planning along with multi-leaf collimators to shape the dose distribution.

A system and method of diagnostic imaging is provided that includes positioning a subject in an imaging device, collecting positioning information of the subject from at least one sensor disposed in proximity of the imaging device, and determining a relative position of the subject within the imaging device from at least the position information. The present invention automatically selects a proper attenuation filter configuration, corrects patient centering, and corrects noise prediction errors, thereby increasing dose efficiency and tube output.

The invention provides methods and compositions for treating lactose intolerance. In embodiments, the invention provides methods and composition for decreasing symptoms of lactose intolerance by administering to an individual suffering from lactose intolerance increasing doses of lactose using a protocol such that at the end of treatment the individual's symptoms of lactose intolerance are decreased and such that symptoms remain decreased after a period of time.

A system and method are used to manufacture a device using at least one exposure step. Each exposure step projects a patterned beam of radiation onto a substrate. The patterned beam includes a plurality of pixels. Each pixel delivers a radiation dose no greater than a predetermined normal maximum dose to the target portion in the exposure step and / or at least one selected pixel delivers an increased radiation dose, greater than the normal maximum dose. The increased dose may be delivered to compensate for the effect of a defective element at a known position in the array on a pixel adjacent a selected pixel or compensate for underexposure of the target portion at the location of a selected pixel resulting from exposure of that location to a pixel affected by a known defective element in another exposure step.

A spray device including a casing and a spray bottle. A closing element is arranged in a nozzle. The closing element substantially fills the nozzle in order to minimize residual amounts of a drug in the nozzle. The overall purpose is to protect the spray device from contamination and evaporation. A method for manufacturing with as few parts as possible a spray device that by usually manual action causes the spray bottle to effect a pumping movement which triggers a spray dose through the nozzle. The device is intended to increase dose accuracy and facilitate the actual pumping.

The invention relates to a spray device which comprises a casing (1 ) and a spray bottle (2) and which has in its nozzle (5) a closing element which at the same time substantially fills the nozzle in order to minimise residual amounts of, preferably, a drug 5 in the nozzle, the overall purpose being to protect the spray device from contamination and evaporation. The invention further relates to a method for manufacturing with as few parts as possible a spray device which by usually manual action causes the spray bottle (2) to effect a pumping movement which triggers a spray dose through the nozzle (5). The device is intended to increase dose accuracy and facilitate the actual pumping.

The present invention relates to a sustained release composition containing pregabalin or a pharmaceutically acceptable salt thereof using a gastroretentive drug delivery system (GRDDS), an oral sustained release formulation containing the composition, and a method for preparing the same. The sustained release composition and the formulation containing the same, according to the present invention, provide a gastroretentive drug delivery system in which a coating portion including sugars or derivatives thereof and a plasticizer is introduced on an external surface of pregabalin having a less stable structure to ensure stability and improve compatibility with an excipient, simultaneously, and the release rate is effectively controlled to increase dosing convenience, leading to increase the compliance of a subject to be administered, and thus the present invention can exhibit improved treatment or prevention effects on various mental disorders, such as neuropathic pain, epilepsy, and fibromyalgia, which could not be previously easily accomplished due to the characteristics of pregabalin.

The invention relates to the field of proteins, in particular to application of recombinant human calcineurin B subunit, and mainly provides application of rhCNB to preparation of a medicine for killing and / or inhibiting a liver cancer cell Bel-7402. After continuous medication for 6 times, medication groups of rhCNB for injection with doses of 10 mg / kg, 20 mg / kg and 40 mg / kg all have a relatively good inhibiting effect on the growth of human liver cancer cell Bel-7402 solid tumors. Subsequent testing results show that the effects of high-dose, middle-dose and increasing-dose medication groups are superior to that of a low-dose medication group, and the treating effect of rhCNB for injection is equivalent to those of recombinant human interleukin-2 for injection and hydroxycamptothecine for injection in a solvent control group. The results of d7 testing after final medication show that the high-dose group has the optimum controlling effect (p is smaller than 0.01) on tumor cell proliferation, which is superior to those of other dose groups and a positive control group, and equivalent to those of a hydroxycamptothecine medication group and the increasing-dose group (p is smaller than 0.05).

Photon-based radiosurgery is widely used for treating local and regional tumors. The key to improving the quality of radiosurgery is to increase the dose falloff rate from high dose regions inside the tumor to low dose regions of nearby healthy tissues and structures. Dynamic photon painting (DPP) further increases dose falloff rate by treating a target by moving a beam source along a dynamic trajectory, where the speed, direction and even dose rate of the beam source change constantly during irradiation. DPP creates dose gradient that rivals proton Bragg Peak and outperforms Gamma Knife® radiosurgery.

Certain R5 virus tropic HIV-1 subjects with viral load effectively conventionally controlled using HAART, i.e., subject having less than 50 viral copies / mL (<50 cp / mL), may be substantially more susceptible than others to effective monotherapy treatment using anti-CCR5 agents, e.g, PRO 140 mAbs. Certain HIV-1 subjects using PRO 140 monotherapy treatment may experience prolonged or unlimited time periods with actual undetectable viral loads, extremely low viral load counts ≤1 cp / mL, very low, or low levels, or at conventionally undetectable levels, during monotherapy. Increasing dose amounts of anti-CCR5 agents, e.g., PRO 140, from 350 mg to 525 mg or 700 mg, may beneficially suppress a subject's viral load count before, during, and / or maintain effective prolonged monotherapy and may shorten the period of time necessary to determine if a subject will respond positively to PRO 140 monotherapy to less than eight (8) weeks. This invention includes protocols, methods, and kits.

The present invention provides a reservoir compartment adapter for use with a fluid delivery device. The adapter includes a first end adapted for coupling with a fluid delivery device, a second end adapted for coupling with a connector, and a structure between the first end and the second end including an interior space for receiving the reservoir, wherein an extended reservoir compartment for accommodating the reservoir is adapted to be formed when the first end is coupled to the fluid delivery device, and the reservoir is adapted to be secured in the extended reservoir compartment when the connector is coupled to the second end. The adapter allows a user of a delivery device accommodating reservoirs of a certain size to manage periods where increased medication dosage is needed without the burden of carrying a larger delivery device for accommodating reservoirs filled with the increased dosage.

The invention discloses the application of total triterpenoids of Pteridocarpus to protect chronic alcoholic liver injury, and belongs to the technical field of biomedicine. A dose-escalating drinking method was used to simulate the process of chronic alcohol-induced liver injury in humans. The total triterpenoids of Pteridocarpus can inhibit GOT and GPT to a certain extent, and the inhibitory effect is positively correlated with the dose. The purified total triterpenoids of Viburnum fern have strong antioxidant capacity in vivo, and its hepatoprotective mechanism may be to effectively alleviate the damage caused by alcohol to the liver by enhancing the body's antioxidant capacity and effectively removing unfavorable free radicals. Medium and high doses of purified total triterpenoids of Viburnum fern can effectively alleviate the oxidative damage caused by lipid peroxidation and free radical attack in the liver, reduce the degree of hepatocyte enlargement, necrosis and fatty degeneration, and regulate cells to restore normal metabolism and Physiological function, its effect is better than that of the positive control drug bifendate within a certain concentration range, indicating that the total triterpenoids of Pteridocarpus have a certain protective effect on chronic alcoholic liver injury.